ABOUT CELL SOURCE
Next-Generation Immunotherapy – Safer Transplantation and More Effective Cancer Treatment
Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. Our patented Veto Cell technology is the centerpiece of treatment protocols that represent major breakthroughs in immune system management – safe and selective “tolerizing” of immune response.
Our technology addresses one of the most fundamental challenges in the field of immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells and tissue while continuing to attack all other potential threats.
Collaborative Partnerships
Cell Source is collaborating with top-tier scientists and institutions such as Dr. Zelig Eshhar, the inventor of CAR-T therapy, and the MD Anderson Cancer Center, the world leader in bone marrow transplants and cancer treatment.
Product Pipeline
Cell Source is actively evaluating its Veto Cell-based therapies in Clinical and Pre-Clinical trials.
Scientific Publications
Cell Source’s scientific leadership, allogeneic HSCT protocols, and Veto Cell technologies have been featured and discussed in immunology’s leading peer-reviewed publications.
Scientific Advisory Board
